The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Association of sBCMA with measures of disease burden & response to linvoseltamab in R/R myeloma
Anita Boyapati, PhD, Regeneron Pharmaceuticals, Tarrytown, NY, discusses the results of a study which showed that soluble BCMA (sBCMA) concentration is modestly correlated with measures of disease burden in patients with relapsed/refractory multiple myeloma (R/R MM) treated with linvoseltamab. The study also showed that patients with very high baseline sBCMA demonstrated high overall response rates (ORR) to linvoseltamab. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Regeneron employee and shareholder
